<PAGE> 1
SCHEDULE 14A
(RULE 14a-101)
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. )
FILED BY THE REGISTRANT [X] FILED BY A PARTY OTHER THAN THE REGISTRANT [ ]
- --------------------------------------------------------------------------------
Check the appropriate box:
[ ] Preliminary Proxy Statement
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
ADVANCED MAGNETICS, INC.
(Name of Registrant as Specified In Its Charter)
PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1) Title of each class of securities to which transaction applies:
2) Aggregate number of securities to which transaction applies:
3) Per unit price or other underlying value of transaction computed pursuant
to Exchange Act
Rule 0-11:
4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
1) Amount Previously Paid:
2) Form, Schedule or Registration Statement No.:
3) Filing Party:
4) Date Filed:
- --------------------------------------------------------------------------------
<PAGE> 2
ADVANCED MAGNETICS, INC.
61 MOONEY STREET
CAMBRIDGE, MASSACHUSETTS 02138
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON FEBRUARY 3, 1998
------------------------
The Annual Meeting of Stockholders of Advanced Magnetics, Inc. (the
"Company") will be held at the offices of the Company, 61 Mooney Street,
Cambridge, Massachusetts 02138 on Tuesday, February 3, 1998 at 10:00 a.m., local
time, to consider and act upon the following matters:
1. To elect seven directors to serve for the ensuing year.
2. To transact such other business as may properly come before the meeting
or any adjournment thereof.
Stockholders of record at the close of business on December 8, 1997 will be
entitled to vote at the meeting or any adjournment thereof. A list of the
stockholders of record entitled to vote shall be available for inspection at the
principal office of the Company for ten days prior to the Annual Meeting. The
stock transfer books of the Company will remain open.
By Order of the Board of Directors
MARLENE KAPLAN GOLDSTEIN,
Secretary
Cambridge, Massachusetts
December 22, 1997
WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, DATE AND
SIGN THE ENCLOSED PROXY AND MAIL IT PROMPTLY IN THE ENCLOSED ENVELOPE IN ORDER
TO ASSURE REPRESENTATION OF YOUR SHARES. NO POSTAGE NEED BE AFFIXED IF THE PROXY
IS MAILED IN THE UNITED STATES.
<PAGE> 3
ADVANCED MAGNETICS, INC.
61 MOONEY STREET
CAMBRIDGE, MASSACHUSETTS 02138
PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON FEBRUARY 3, 1998
This Proxy Statement is furnished in connection with the solicitation of
proxies by the Board of Directors of Advanced Magnetics, Inc. (the "Company")
for use at the Annual Meeting of Stockholders to be held at the offices of the
Company at 61 Mooney Street, Cambridge, Massachusetts 02138, on Tuesday,
February 3, 1998 and at any adjournment of the Annual Meeting. All proxies will
be voted in accordance with the stockholders' instructions, and if no choice is
specified, the proxies will be voted in favor of the matters set forth in the
accompanying Notice of Meeting. Any proxy may be revoked by a stockholder at any
time before its exercise by delivery of written revocation to the Secretary of
the Company.
December 8, 1997 was the record date for the determination of stockholders
entitled to vote at the meeting. On that date, there were an aggregate of
6,729,526 shares of Common Stock of the Company outstanding and entitled to
vote. Each share is entitled to one vote.
The Company's Annual Report for fiscal 1997 was mailed to the stockholders
with the mailing of this Notice of Meeting and Proxy Statement on or about
December 22, 1997.
VOTES REQUIRED
The representation in person or by proxy of at least a majority of the
outstanding shares of Common Stock entitled to vote at the meeting is necessary
to constitute a quorum for the transaction of business. Directors are elected by
a plurality of the votes cast by stockholders entitled to vote at the meeting.
The affirmative vote of the holders of a majority of the shares of Common Stock
present or represented, and voting, at the meeting is required for all other
matters being submitted to stockholders at the meeting. Votes withheld from any
nominee, abstentions and broker "non-votes" are counted as present or
represented for purposes of determining the presence or absence of a quorum for
the meeting. A "non-vote" occurs when a nominee holding shares for a beneficial
owner votes on one proposal, but does not vote on another proposal because, in
respect of such other proposal, the nominee does not have discretionary voting
power and has not received instructions from the beneficial owner. Abstentions
are included in the number of shares present or represented and voting on each
matter. Broker "non-votes" are not so included. Votes will be tabulated by
American Stock Transfer and Trust Company as Transfer Agent/Registrar of the
Company.
<PAGE> 4
PRINCIPAL STOCKHOLDERS
The following table sets forth certain information, as of December 8, 1997,
with respect to the beneficial ownership of the Company's Common Stock by (i)
each person known by the Company to own beneficially more than 5% of the
outstanding shares of Common Stock, (ii) the directors, (iii) the chief
executive officer and each of the four other most highly compensated executive
officers of the Company as of September 30, 1997 whose annual compensation
exceeded $100,000 (the "Named Officers") and (iv) all directors and officers of
the Company as a group:
<TABLE>
<CAPTION>
PERCENTAGE OF
NAME AND ADDRESS NUMBER OF COMMON STOCK
OF BENEFICIAL OWNER(1) SHARES OUTSTANDING
---------------------- --------- -------------
<S> <C> <C>
Marlene Kaplan Goldstein(2)(3)................ 705,937 10.49%
Jerome Goldstein(2)(3)(4)..................... 699,272 10.37%
BVF Partners L.P.(5).......................... 474,200 7.05%
333 West Wacker Drive, Suite 1600
Chicago, Illinois 60606
Eiken Chemical Co., Ltd....................... 375,000 5.57%
1-33-8 Hongo
Bunkyo-Ku Tokyo, Japan
Leslie Goldstein(6)........................... 326,250 4.84%
Ernest V. Groman, Ph.D.(7).................... 139,436 2.07%
Edward B. Roberts, Ph.D.(8)................... 104,040 1.54%
Richard L. McIntire(9)........................ 99,000 1.47%
George M. Whitesides, Ph.D.(10)............... 72,000 1.07%
Thomas Coor, Ph.D.(11)........................ 19,500 *
Roger E. Travis(12)........................... 18,861 *
Paula M. Jacobs, Ph.D.(13).................... 18,708 *
Jerome M. Lewis, Ph.D.(14).................... 10,627 *
Leonard M. Baum(15)........................... 7,174 *
Joseph Lassiter, III.......................... 0 *
Michael Loberg................................ 0 *
All directors and executive officers as a
group (17 persons)(16)...................... 2,203,785 32.21%
</TABLE>
- ---------------
* Less than 1%.
(1) Unless otherwise indicated, each stockholder referred to above has sole
voting and investment power with respect to the shares listed and the
address of each stockholder is: c/o Advanced Magnetics, Inc., 61 Mooney
Street, Cambridge, Massachusetts 02138.
(2) Jerome Goldstein and Marlene Kaplan Goldstein are husband and wife, and
each disclaims control or beneficial ownership of shares held by the other.
(3) Includes 42,000 shares held by the Kaplan Goldstein Family Foundation, a
charitable foundation whose trustees are Jerome Goldstein, Marlene Kaplan
Goldstein and their two adult children.
(4) Includes 11,250 shares issuable to Jerome Goldstein pursuant to options
exercisable on or before February 6, 1998.
(5) Based upon a Schedule 13D filed with the Securities and Exchange Commission
on October 29, 1996, and amended on May 16, 1997, BVF Partners L.P.
("Partners") is the beneficial owner of 474,200 shares of stock. BVF, Inc.,
One Sansome Street, 39th Floor, San Francisco, California 94104, is an
2
<PAGE> 5
investment advisor to and general partner of Partners. BVF, Inc. shares
voting and dispositive power over the 474,200 shares held by Partners.
(6) Includes 21,750 shares held by Leslie Goldstein for the following
charitable foundation and trusts: 3,750 shares held by him as Trustee of
the Allan Goldstein Children's Trust, 3,000 shares held by him as Trustee
for his children and 15,000 shares held by him as Trustee of the Leslie and
Roslyn Goldstein Foundation. Includes 12,000 shares issuable to Leslie
Goldstein pursuant to options exercisable on or before February 6, 1998.
(7) Includes 5,250 shares owned by Dr. Groman's son, 26,000 shares held in
trust for the benefit of Dr. Groman's sons and 6,500 shares issuable to Dr.
Groman pursuant to options exercisable on or before February 6, 1998.
(8) Includes 34,500 shares held by Dr. Roberts as trustee for his children and
4,500 shares issuable to Dr. Roberts pursuant to options exercisable on or
before February 6, 1998.
(9) Includes 50,600 shares held in joint tenancy with Mr. McIntire's wife and
12,000 shares issuable to Mr. McIntire pursuant to options exercisable on
or before February 6, 1998.
(10) Includes 12,000 shares issuable to Dr. Whitesides pursuant to options
exercisable on or before February 6, 1998.
(11) Includes 1,000 shares held in custodial accounts for Dr. Coor's sons and
12,000 shares issuable to Dr. Coor pursuant to options exercisable on or
before February 6, 1998.
(12) Includes 5,000 shares held by the Ellis Travis Trust as to which Mr. Travis
is trustee and 4,500 shares issuable to Mr. Travis pursuant to options
exercisable on or before February 6, 1998. Does not include 3,000 shares
owned by his adult daughters as to which shares Mr. Travis disclaims
beneficial ownership.
(13) Includes 2,228 shares held in a custodial account for Dr. Jacobs' daughter
and 9,750 shares issuable to Dr. Jacobs pursuant to options exercisable on
or before February 6, 1998.
(14) Includes 9,750 shares issuable to Dr. Lewis pursuant to options exercisable
on or before February 6, 1998.
(15) Includes 5,000 shares issuable to Mr. Baum pursuant to options exercisable
on or before February 6, 1998.
(16) Includes 188,328 shares held in family or charitable trusts and custodial
accounts for various directors' and officers' children and 112,102 shares
issuable under options exercisable on or before February 6, 1998.
ELECTION OF DIRECTORS
The persons named in the enclosed proxy will vote to elect as directors the
seven nominees named below, all of whom are now directors of the Company, unless
authority to vote for the election of any or all of the directors is withheld by
marking the proxy to that effect.
Each director will be elected to hold office until the next annual meeting
of stockholders and until his successor is elected and qualified, or until his
earlier death, resignation or removal. Each of the nominees has indicated his
willingness to serve, if elected, but if a nominee should be unable to serve,
the proxies may be voted for a substitute nominee designated by management.
Thomas Coor, Richard McIntire and Roger Travis who have served as directors
of the Company since 1983, 1982 and 1981, respectively, and who would have been
subject to re-election as directors at the Meeting, have decided not to stand
for re-election for personal reasons. The Company expresses its thanks to
Messrs. Coor, McIntire and Travis for their years of service on the Board of
Directors.
The following table sets forth the name and age of each nominee and the
positions and offices held by him, his principal occupation and business
experience during the past five years, the year of the commence-
3
<PAGE> 6
ment of his term as a director of the Company, the number of shares of Common
Stock of the Company beneficially owned by him on December 8, 1997 and the
percentage of all outstanding shares of Common Stock owned by him.
<TABLE>
<CAPTION>
NUMBER PERCENTAGE
COMMENCEMENT OF SHARES OF
NAME, AGE, PRINCIPAL OCCUPATION OF TERM AS A BENEFICIALLY COMMON STOCK
AND BUSINESS EXPERIENCE DIRECTOR OWNED(1) OUTSTANDING
------------------------------- ------------ ------------ ------------
<S> <C> <C> <C>
Leonard M. Baum..................................... 1997 7,174(2) *
Mr. Baum, age 44, has been President and Chief
Operating Officer of the Company since June 1997
and has been a Senior Vice President of the
Company since September 1994. He was formerly
employed by Squibb Diagnostics from March 1986 to
September 1994, most recently as Senior Director,
Worldwide Regulatory Affairs.
Jerome Goldstein.................................... 1981 699,272(3) 10.37%
Mr. Goldstein, age 58, is a founder of the Company
and has been Chairman of the Board of Directors,
Chief Executive Officer and Treasurer since the
Company's organization in November 1981. Mr.
Goldstein was President of the Company from the
Company's organization in November 1981 until June
1997.
Leslie Goldstein.................................... 1981 326,250(4) 4.84%
Mr. Goldstein, age 62, has been engaged in
investment analysis as an associate of SRG
Associates since June 1977. SRG Associates is a
division of Fahnestock & Company, Inc., a security
broker-dealer. Mr. Goldstein is the brother of
Jerome Goldstein.
Joseph Lassiter, III................................ 1997 0 *
Professor Lassiter, age 50, has been a Lecturer
and Professor at the Harvard Business School since
September 1996. He was the President of Wildfire
Communications, Inc., a telecommunications
software company, from July 1994 to February 1996,
and was Vice President at Teradyne, Inc., a
manufacturer of automatic test equipment, from
January 1977 to February 1994. He is a director of
Security Dynamics Technologies, Inc.
Michael Loberg...................................... 1997 0 *
Mr. Loberg, age 50, has been Chief Executive
Officer of NitroMed, Inc. since September 1997.
Prior to that, he served for twenty years in
various senior management positions at
Bristol-Myers Squibb, including President of
Squibb Diagnostics, President of BMS Northern
Europe and President of BMS Specialty
Pharmaceuticals.
Edward B. Roberts, Ph.D............................. 1982 104,040(5) 1.54%
Professor Roberts, age 62, has been Professor at
the Sloan School at the Massachusetts Institute of
Technology since 1961. He was a co-founder and the
Chairman of Pugh-Roberts Associates, Inc., a
management consulting firm that is now a division
of PA Consulting Group, Inc. He is also a general
partner of Zero Stage Capital Management, L.P., a
venture capital limited partnership. He is also a
director of SelfCare, Inc., PegaSystems, Inc. and
Medical Information Technology Inc.
</TABLE>
4
<PAGE> 7
<TABLE>
<CAPTION>
NUMBER PERCENTAGE
COMMENCEMENT OF SHARES OF
NAME, AGE, PRINCIPAL OCCUPATION OF TERM AS A BENEFICIALLY COMMON STOCK
AND BUSINESS EXPERIENCE DIRECTOR OWNED(1) OUTSTANDING
------------------------------- ------------ ------------ ------------
<S> <C> <C> <C>
George M. Whitesides, Ph.D. ........................ 1981 72,000(6) 1.07%
Professor Whitesides, age 58, has been a Professor
of Chemistry at Harvard University since July
1982. He is a director of Dexter Corporation, a
manufacturer of specialty material product, and
Geltex Inc., a biopharmaceutical company.
</TABLE>
- ---------------
* Less than 1%.
(1) Unless otherwise indicated, each person listed above has sole voting and
investment power with respect to the shares listed.
(2) See note 15 to the table set forth under the caption "Principal
Stockholders."
(3) See notes 2, 3 and 4 to the table set forth under the caption "Principal
Stockholders."
(4) See note 6 to the table set forth under the caption "Principal
Stockholders."
(5) See note 8 to the table set forth under the caption "Principal
Stockholders."
(6) See note 10 to the table set forth under the caption "Principal
Stockholders."
BOARD AND COMMITTEE MEETINGS
The Board of Directors met four times during the fiscal year ended
September 30, 1997. Each director attended at least 75% of the meetings of the
Board of Directors and all the Committees on which he served with the exception
of Mr. Whitesides, who attended one meeting and Mr. Loberg and Mr. Lassiter, who
were elected to the Board during the year. Mr. Loberg attended, but Mr. Lassiter
did not attend, the one meeting of the Board of Directors that was held during
their tenure as directors in the fiscal year ended September 30, 1997.
Jerome Goldstein, Roger Travis and Edward Roberts serve as members of the
Audit Committee of the Board of Directors. The Audit Committee oversees
generally the financial controls and practices of the Company. The Audit
Committee conducted two formal meetings apart from Board of Directors meetings
during the 1997 fiscal year.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Exchange Act requires the Company's directors,
executive officers and holders of more than 10% of the Company's Common Stock
(collectively, "Reporting Persons") to file with the Commission initial reports
of ownership and reports of changes in ownership of Common Stock of the Company.
Such persons are required by regulations of the Commission to furnish the
Company with copies of all such filings. Based on its review of the copies of
such filings received by it with respect to the fiscal year ended September 30,
1997, and written representations from certain Reporting Persons, the Company
believes that all Reporting Persons complied with all Section 16(a) filing
requirements in the fiscal year ended September 30, 1997, with the following
exceptions: Paula Jacobs filed one late report on January 13, 1997 covering five
transactions; Lee Josephson filed two late reports on February 14, 1997 and
March 11, 1997, each covering one transaction; Jerome Lewis filed one late
report on January 13, 1997 covering six transactions; Edward Roberts filed one
late report on January 13, 1997 covering four transactions; and Mark Roessel
filed one late report on February 14, 1997 covering five transactions.
5
<PAGE> 8
COMPENSATION AND OTHER INFORMATION
CONCERNING DIRECTORS AND OFFICERS
EXECUTIVE COMPENSATION SUMMARY
The following table sets forth the annual and long-term compensation of
each of the Company's Named Officers as of the end of fiscal year 1997 for each
of the fiscal years ended September 30, 1997, 1996 and 1995:
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG-TERM COMPENSATION
AWARDS(2)
ANNUAL ---------------------------------
COMPENSATION(1) SECURITIES
----------------- UNDERLYING ALL OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY($) OPTIONS/SARS(#) COMPENSATION($)
--------------------------- ---- --------- --------------- ----------------
<S> <C> <C> <C> <C>
Jerome Goldstein......................... 1997 228,115 30,000(3) 16,800(4)
Chairman of the Board of Directors, 1996 220,738 0 11,215(4)
Chief Executive Officer and Treasurer 1995 211,102 0 12,875(4)
Leonard M. Baum.......................... 1997 194,104 20,000(3) 2,000(5)
President and Chief Operating Officer 1996 186,231 0 2,000(5)
1995 177,234 0 2,000(5)
Ernest V. Groman, Ph.D.(6)............... 1997 126,335 8,000(3) 2,000(5)
Vice President -- Research
Paula M. Jacobs, Ph.D.................... 1997 122,861 9,000(3) 2,000(5)
Vice President -- Development 1996 118,500 0 2,000(5)
1995 113,462 4,000 2,000(5)
Jerome M. Lewis, Ph.D. .................. 1997 116,413 8,000(3) 2,000(5)
Vice President -- Scientific Operations 1996 112,115 0 2,000(5)
1995 107,114 4,000 2,000(5)
</TABLE>
- ---------------
(1) Excludes perquisites and other personal benefits, the aggregate annual
amount of which for each officer was less than the lesser of $50,000 or 10%
of the total salary and bonus reported.
(2) The Company did not grant any restricted stock awards or stock appreciation
rights or make any long term incentive plan payouts during the fiscal years
ended September 30, 1997, 1996 and 1995.
(3) Options granted pursuant to the repricing of options described under the
caption "Option Repricing" and disclosed in the table "Ten Year Option
Repricing" set forth below.
(4) Includes $14,800, $9,215 and $10,875 in premiums on a term life insurance
policy related to coverage in the fiscal years ended September 30, 1997,
1996 and 1995, respectively, in the event of the death of Mr. Goldstein and
his wife to a trust for the benefit of their children and $2,000 in
contributions for Mr. Goldstein's benefit to the Company's 401(k) plan.
(5) Represents amount contributed for the benefit of the Named Officers to the
Company's 401(k) plan.
(6) Dr. Groman was elected by the Board of Directors as an executive officer in
June 1997.
6
<PAGE> 9
OPTION GRANTS IN THE LAST FISCAL YEAR
The following table sets forth grants to the Named Officers of stock
options during the fiscal year ended September 30, 1997:
OPTION/SAR GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
INDIVIDUAL GRANTS
---------------------------------------------------------
PERCENT OF POTENTIAL REALIZABLE
TOTAL VALUE AT ASSUMED
NUMBER OF OPTIONS/ ANNUAL RATES OF
SECURITIES SARs STOCK PRICE
UNDERLYING GRANTED TO APPRECIATION FOR
OPTION/ EMPLOYEES EXERCISE OR OPTION TERM(1)
SARs IN FISCAL BASE PRICE EXPIRATION --------------------
NAME GRANTED(#) YEAR ($/SH) DATE 5%($) 10%($)
- ---- ---------- ---------- ----------- ---------- -------- --------
<S> <C> <C> <C> <C> <C> <C>
Jerome Goldstein......... 30,000(2) 9.59 11.125 8/5/07 209,894 531,912
Leonard M. Baum.......... 20,000(2) 6.39 11.125 8/5/07 139,929 354,608
Paula M. Jacobs,
Ph.D. ................. 2,000(3) 0.64 15.000 11/6/06 18,867 47,812
7,000(2) 2.24 11.500 7/3/07 50,626 128,296
Jerome M. Lewis,
Ph.D. ................. 2,000(3) 0.64 15.000 11/6/06 18,867 47,812
6,000(2) 1.92 11.500 7/3/07 43,394 109,968
Ernest V. Groman,
Ph.D. ................. 2,000(3) 0.64 15.000 11/6/06 18,867 47,812
6,000(2) 1.92 11.500 7/3/07 43,394 109,968
</TABLE>
- ---------------
(1) Amounts reported in these columns represent amounts that may be realized
upon exercise of the options immediately prior to the expiration of their
term assuming the specified compounded rates of appreciation (5% and 10%) on
the Company's Common Stock over the term of the options. These numbers are
calculated based on rules promulgated by the Securities and Exchange
Commission and do not reflect the Company's estimate of future stock price
growth. Actual gains, if any, on stock option exercises and Common Stock
holdings are dependent on the timing of such exercise and the future
performance of the Company's Common Stock. There can be no assurance that
the rates of appreciation assumed in this table can be achieved or that the
amounts reflected will be received by the individuals.
(2) Options granted pursuant to the repricing of options described under the
caption "Option Repricing."
(3) Options granted under the Company's 1993 Stock Plan at an exercise price
equal to the fair market value of the Company's Common Stock on the date of
grant. The options have a term of ten years from the date of grant and
become exercisable as to 25% of the shares on each of the first four
anniversaries of the date of grant until such options are fully exercisable
thereafter.
7
<PAGE> 10
OPTION EXERCISES AND FISCAL YEAR-END VALUES
The following table sets forth information as to the Named Officers with
respect to options to purchase the Company's Common Stock held by each Named
Officer, including (i) the number of shares of Common Stock purchased upon
exercise of options in fiscal 1997, (ii) the net value realized upon such
exercise, (iii) the number of unexercised options outstanding at September 30,
1997 and (iv) the value of such unexercised options at September 30, 1997:
AGGREGATED OPTION/SAR EXERCISES IN LAST FISCAL YEAR AND
SEPTEMBER 30, 1997 OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF
SECURITIES UNDERLYING VALUE OF UNEXERCISED
UNEXERCISED OPTIONS/SARs IN-THE-MONEY OPTIONS/SARs
SHARES VALUE AT SEPTEMBER 30, 1997(#) AT SEPTEMBER 30, 1997($)(2)
ACQUIRED ON REALIZED ---------------------------- ----------------------------
NAME EXERCISE(#) ($)(1) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- ---- ----------- -------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
Jerome Goldstein.......... -- -- 11,250 18,750 -- --
Leonard M. Baum........... -- -- 5,000 15,000 -- --
Paula M. Jacobs, Ph.D..... 2,500 17,918 9,250 6,250 8,845 --
Jerome M. Lewis, Ph.D. ... 1,000 9,042 9,250 5,750 6,272 --
Ernest V. Groman,
Ph.D. .................. -- -- 6,000 5,750 4,704 --
</TABLE>
- ---------------
(1) Amounts disclosed in this column do not reflect amounts actually received by
the Named Officers but are calculated based on the difference between the
fair market value of the Company's Common Stock on the date of exercise and
the exercise price of the options. The Named Officers will receive cash only
if and when they sell the Common Stock issued upon exercise of the options,
and the amount of cash received by such individuals is dependent on the
price of the Company's Common Stock at the time of such sale.
(2) Value is based on the difference between the option exercise price and the
fair market value at September 30, 1997 ($10.6875 per share as quoted on the
American Stock Exchange) multiplied by the number of shares underlying the
option.
8
<PAGE> 11
OPTION REPRICING
The following table sets forth information concerning all of the repricings
of options held by officers of the Company who were officers at the time of the
repricing over the last ten years, including (i) the date of the repricing, (ii)
the number of shares subject to the repriced options, (iii) the market price at
the time of the repricing, (iv) the exercise price prior to repricing, (v) the
new exercise price and (vi) the original option term remaining at the date of
repricing:
TEN YEAR OPTION REPRICING
<TABLE>
<CAPTION>
LENGTH OF
ORIGINAL
NUMBER OF MARKET PRICE OPTION TERM
OPTIONS OF STOCK AT EXERCISE PRICE REMAINING AT DATE
REPRICED TIME OF AT TIME OF NEW OF REPRICING OR OF
OR REPRICING OR REPRICING OR EXERCISE AMENDMENT
NAME DATE AMENDED(#) AMENDMENT AMENDMENT PRICE (YEARS)
- ---- -------- ---------- ------------ -------------- -------- ------------------
<S> <C> <C> <C> <C> <C> <C>
Jerome Goldstein........ 8/5/97(1) 28,828 $ 11.125 $ 15.270 $ 11.125 7
Chairman of the Board 1,172 11.125 13.880 11.125 7
of Directors, Chief
Executive Officer and
Treasurer
Leonard M. Baum......... 8/5/97(1) 20,000 11.125 16.375 11.125 7
President and Chief
Operating Officer
Paula M. Jacobs,
Ph.D. ................ 7/3/97(2) 2,000 11.500 14.875 11.500 7
Vice President -- 2,000 11.500 22.000 11.500 8
Development 2,000 11.500 15.000 11.500 9
1,000 11.500 13.375 11.500 6
8/5/92(3) 2,000 11.875 19.75 11.875 10
11/30/90(4) 3,000 7.833 9.667 7.833 9
Jerome M. Lewis,
Ph.D. ................ 7/3/97(2) 2,000 11.500 14.875 11.500 7
Vice President -- 2,000 11.500 22.000 11.500 8
Scientific Operations 2,000 11.500 15.000 11.500 9
8/5/92(3) 2,000 11.875 19.75 11.875 10
Ernest V. Groman,
Ph.D. ................ 7/3/97(2) 2,000 11.500 14.875 11.500 7
Vice President -- 2,000 11.500 22.000 11.500 8
Research 2,000 11.500 15.000 11.500 9
11/30/90(4) 3,000 7.833 9.667 7.833 9
Dennis R. Lawler........ 7/3/97(2) 1,500 11.500 14.875 11.500 7
Vice President -- 2,000 11.500 22.000 11.500 8
Quality Control 2,000 11.500 15.000 11.500 9
James A. Matheson....... 7/3/97(2) 2,000 11.500 18.250 11.500 9
Vice President -- 1,000 11.500 15.000 11.500 9
Finance
Mark C. Roessel......... 7/3/97(2) 1,000 11.500 13.375 11.500 6
Vice President -- 2,000 11.500 12.125 11.500 6
Regulatory Affairs 2,000 11.500 14.875 11.500 7
2,000 11.500 22.000 11.500 8
2,000 11.500 15.000 11.500 9
Lee Josephson, Ph.D. ... 11/30/90(4) 3,000 7.833 9.667 7.833 9
Former Vice
President -- Research
Anthony Annese.......... 11/30/90(4) 3,000 7.833 9.667 7.833 9
Former Vice
President -- Finance
</TABLE>
- ---------------
(1) Options exchanged as of August 5, 1997 are held by members of the Company's
Board of Directors who are employees of the Company. The terms of the
exchange call for immediate vesting of one-half of the
9
<PAGE> 12
option holder's previously-vested options. The remainder of the options
granted under the exchange vest 25% annually commencing one year from the
date of the exchange.
(2) Options exchanged as of July 3, 1997 are options held by officers of the
Company who do not serve on the Board of Directors. The terms of the
exchange call for immediate vesting of one-half of the option holder's
previously-vested options. The remainder of the options granted under the
exchange vest 25% annually commencing one year from the date of the
exchange.
(3) Options granted on August 5, 1992 are exercisable over the same period of
time and on the same schedule as the options for which they were exchanged.
(4) Options granted on November 30, 1990 are exercisable over the same period of
time and on the same schedule as the options for which they were exchanged.
10
<PAGE> 13
REPORT ON EXECUTIVE COMPENSATION AND OPTION REPRICING
BY THE BOARD OF DIRECTORS
To Our Stockholders:
The Board of Directors of the Company is responsible for establishing and
administering the Company's executive compensation programs. The Company's
executive compensation policies rely on regular cash salaries and significant
equity incentives in the form of stock options.
Salaries of the five highest paid executives are listed on the Executive
Compensation Summary table found on page 6. On an annual basis, the Board
reviews these salaries and, while it is not required to, it may in its
discretion increase the salaries. The Board has typically adjusted each of its
executives' compensation by the same percentage amount. The amount of the annual
increases has historically reflected the Board's subjective assessment of the
salary level necessary for the Company to remain at the approximate median in
compensation levels when compared to other biopharmaceutical companies of
comparable size and geographical location (which together comprise a subset of
the Company's Peer Group Index referred to in the Performance Graph below), and
the Board's subjective judgment as to Company performance. In fiscal 1997, the
Board determined the Company's performance primarily by reference to the
progress of the Company's clinical trials and product development efforts. The
Board determined to grant the Named Officers the compensation disclosed in the
Executive Compensation Summary table found on page 6.
In order to align the interests of executives and other employees with
stockholders and motivate them to work for the long-term growth of the Company,
the Company provides significant stock option grants to its employees.
Executives are typically considered every two years for stock option grants, and
it is the Company's policy to weight total compensation heavily toward equity
compensation through stock options. Options are generally granted at fair market
value and become exercisable ratably over a four year period. The actual number
of stock options granted to executives is not determined pursuant to any
formula, but rather is determined subjectively by the Board in its discretion.
OPTION REPRICING
In July 1997, the Board of Directors considered the options held by the
Company's employees (including executive officers not serving on the Board of
Directors) and the fact that the decline in the price of the Company's Common
Stock has resulted in a substantial number of stock options granted pursuant to
the Company's Stock Option Plans having exercise prices above the recent
historical trading prices for the Common Stock. The Board of Directors believed
the disparity between the exercise price of the options and the then current
market price no longer provided a meaningful incentive to the option holders.
The Board believes that equity participation provides long-term incentive to
employees to remain with the Company and motivates them to maximize stockholder
returns. Recognizing this incentive, the Board determined it to be in the best
interest of the Company and its stockholders to restore the incentives for
employees to remain with the Company and to exert their best efforts on behalf
of the Company by repricing the option exercise price at the then current market
price of $11.50 per share. The repricing was effected by offering option holders
new options in exchange for their old options.
In August 1997, the Board of Directors made the same determination with
regard to the options granted to Messrs. Jerome Goldstein and Baum, employee
directors of the Company, under the Company's 1993 Stock Option Plan, and to the
options granted to all non-employee directors of the Company, under the
Company's 1992 and 1993 Director Plans. The Board voted to allow all directors
(both employee and non-employee) to exchange their options for options under the
Company's 1993 Stock Option Plan exercisable at the then current market price of
$11.125 per share.
Under the provisions of the repricing exchange offered to employees and
directors, of the options exchanged, only one half of the option holder's vested
options remained vested. All unvested options are scheduled to vest annually
over the four years following the exchange. In voting on the proposal, each
director recused himself from voting with respect to the exchange of his own
options.
11
<PAGE> 14
COMPANY PERFORMANCE AND CEO COMPENSATION
The compensation of the Chief Executive Officer has typically been adjusted
annually by the same percentage as the average percentage increase for all of
the Company's employees. In exercising its discretion, the Board takes into
consideration, among other things, the Company's progress in achieving the goals
of the Board of Directors (focusing in recent periods on the Company's product
development and clinical trial progress), and the compensation packages of
executive officers of comparable companies of similar size in the
biopharmaceutical industry.
As a result of the Company's performance and his individual contribution,
Jerome Goldstein was awarded the amounts reflected in the Executive Compensation
Summary table on page 6 in fiscal 1997.
Members of the Board of Directors:
<TABLE>
<S> <C>
Leonard M. Baum Michael Loberg
Thomas Coor Richard L. McIntire
Jerome Goldstein Edward B. Roberts
Leslie Goldstein Roger E. Travis
Joseph Lassiter, III George M. Whitesides
</TABLE>
COMPENSATION OF DIRECTORS
During the fiscal year ended September 30, 1997, directors received no cash
compensation for their services as directors, except for reimbursement of
expenses incurred in connection with attending meetings.
Under the terms of the 1992 Director Plan, each person who was a member of
the Company's Board of Directors on November 5, 1991 (or was appointed to the
Board of Directors thereafter), and who was not an employee or an officer of the
Company, was automatically granted on November 5, 1991 (or the date of their
appointment to the Board of Directors, if thereafter) (the "1992 Initial Grant
Date") an option to purchase 5,000 shares of the Company's Common Stock, and the
right to receive an option to purchase an additional 5,000 shares on each
successive fifth anniversary of the 1992 Initial Grant Date if he or she is then
a member of the Board of Directors. The exercise price of options granted under
the 1992 Director Plan is the fair market value of the Company's Common Stock on
the date the option is granted (subject to adjustment for any dividend, stock
split or other relevant change in the Company's capitalization). Each option
granted under the 1992 Director Plan first becomes exercisable with respect to
20% of the shares subject to such option on the day preceding each annual
anniversary of the date of grant, until the option is exercisable with respect
to all of the shares subject thereto. On November 5, 1996, each of the
non-employee directors received an option to purchase 5,000 shares at an
exercise price of $15.25 per share.
Under the terms of the 1993 Director Plan, each person who was a member of
the Company's Board of Directors on November 10, 1992 (or was appointed to the
Board of Directors thereafter), and who was not an employee or an officer of the
Company, was automatically granted on November 10, 1992 (or the date of their
appointment to the Board of Directors, if thereafter) (the "1993 Initial Grant
Date") an option to purchase 5,000 shares of the Company's Common Stock, and
will receive an option to purchase an additional 5,000 shares on each successive
sixth anniversary of the 1993 Initial Grant Date if he or she is then a member
of the Board of Directors. The exercise price of options granted under the 1993
Director Plan is the fair market value of the Company's Common Stock on the date
the option is granted (subject to adjustment for any dividend, stock split or
other relevant change in the Company's capitalization). Each option granted
under the 1993 Director Plan first becomes exercisable with respect to 20% of
the shares subject to such option on the day preceding each annual anniversary
of the date of grant, until the option is exercisable with respect to all of the
shares subject thereto.
In June 1997, each of the two newly appointed directors, Michael Loberg and
Joseph Lassiter, upon the respective dates of their appointment, were granted an
option to purchase 5,000 shares of the Company's Common Stock under the 1992
Director Plan and an option to purchase 5,000 shares of the Company's
12
<PAGE> 15
Common Stock under the 1993 Director Plan. The exercise price of Mr. Loberg's
options was $11.75. The exercise price of Mr. Lassiter's options was $13.50.
Each director received 10,000 options in total.
Options held by the directors under the 1992 and 1993 Director Plans were
eligible for the option repricing exchange for options granted as described
above.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The Company does not have a Compensation Committee. The Board of Directors
was responsible for determining compensation of executive officers of the
Company. During the fiscal year ended September 30, 1997, Jerome Goldstein, the
Company's Chairman of the Board of Directors, Chief Executive Officer and
Treasurer, participated in the establishment and administration of the Company's
executive compensation programs. Mr. Goldstein abstained from voting with
respect to decisions concerning his compensation as an executive officer of the
Company.
13
<PAGE> 16
STOCK PERFORMANCE GRAPH
The following graph compares the yearly percentage change in the cumulative
total stockholder return on the Company's Common Stock during the five fiscal
years ended September 30, 1997 with the cumulative total return on the American
Stock Exchange Market Value Index and the Company's Peer Groups based on SIC
Code 2835 (in vitro and in vivo diagnostic substances) and SIC Code 2834
(pharmaceutical preparations). Due to recent realignment of the Company's
product portfolio, the Company now considers its peer group to be based on SIC
Code 2834. The comparisons assume $100 was invested on October 1, 1992 in the
Company's Common Stock in the American Stock Exchange Market Value Index and
with the Company's Peer Groups and assumes reinvestment of dividends, if any.
COMPARE CUMULATIVE TOTAL RETURN
AMONG ADVANCED MAGNETICS INC., SIC 2834, SIC 2835
AND AMERICAN STOCK EXCHANGE INDEX
[PERFORMANCE CHART]
(DESCRIPTION OF PERFORMANCE CHART)
<TABLE>
COMPARISON OF CUMULATIVE TOTAL RETURN
OF COMPANY, INDUSTRY INDEX AND BROAD MARKET
<CAPTION>
- -------------------------------- FISCAL YEAR ENDING --------------------------
COMPANY 1992 1993 1994 1995 1996 1997
<S> <C> <C> <C> <C> <C> <C>
ADVANCED MAGNETICS INC 100 114.29 143.96 226.37 146.15 93.96
INDUSTRY INDEX 100 84.90 95.49 138.04 183.15 260.21
BROAD MARKET 100 117.39 119.64 144.16 150.03 182.45
</TABLE>
THE INDUSTRY INDEX CHOSEN WAS:
SIC CODE 2834 - PHARMACEUTICAL PREPARATIONS
THE BROAD MARKET INDEX CHOSEN WAS:
AMERICAN STOCK EXCHANGE
<TABLE>
COMPARISON OF CUMULATIVE TOTAL RETURN
OF COMPANY, INDUSTRY INDEX AND BROAD MARKET
<CAPTION>
- -------------------------------- FISCAL YEAR ENDING --------------------------
COMPANY 1992 1993 1994 1995 1996 1997
<S> <C> <C> <C> <C> <C> <C>
ADVANCED MAGNETICS INC 100 114.29 143.96 226.37 146.15 93.96
INDUSTRY INDEX 100 114.70 106.06 152.88 175.01 187.98
BROAD MARKET 100 117.39 119.64 144.16 150.03 182.45
</TABLE>
THE INDUSTRY INDEX CHOSEN WAS:
SIC CODE 2835 - IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
THE BROAD MARKET INDEX CHOSEN WAS:
AMERICAN STOCK EXCHANGE
The stock price performance shown on the graph is not necessarily
indicative of future price performance. Information used in the graph was
obtained from Media General Financial Services, a source the Company believes is
reliable. However, the Company is not responsible for any errors or omissions in
such information.
14
<PAGE> 17
INDEPENDENT PUBLIC ACCOUNTANTS
The Board of Directors has selected the firm of Coopers and Lybrand L.L.P.,
as the Company's independent accountants for the 1998 fiscal year. Coopers &
Lybrand L.L.P. has served as the Company's independent accountants since the
Company's inception. Representatives of Coopers & Lybrand L.L.P. are expected to
be present at the Annual Meeting. They will have the opportunity to make a
statement if they desire to do so and will also be available to respond to
appropriate questions from stockholders.
OTHER MATTERS
Management does not know of any other matters which may come before the
Annual Meeting. However, if any other matters are properly presented to the
meeting, it is the intention of the persons named in the accompanying proxy to
vote, or otherwise act, in accordance with their judgment on such matters.
All costs of solicitation of proxies will be borne by the Company. In
addition to solicitations by mail, the Company's directors, officers and regular
employees, without additional remuneration, may solicit proxies by telephone,
telegraph and personal interviews. Brokers, custodians and fiduciaries will be
requested to forward proxy soliciting material to the owners of stock held in
their names, and the Company will reimburse them for their out-of-pocket
expenses in this connection.
DEADLINE FOR SUBMISSION OF STOCKHOLDER PROPOSALS
Proposals of stockholders intended to be presented at the 1999 Annual
Meeting of Stockholders must be received by the Company at its principal office
in Cambridge, Massachusetts not later than August 24, 1998 for inclusion in the
proxy statement for that meeting.
By Order of the Board of Directors
MARLENE KAPLAN GOLDSTEIN,
Secretary
December 22, 1997
THE BOARD OF DIRECTORS WELCOMES STOCKHOLDERS WHO WISH TO ATTEND THE
MEETING. WHETHER OR NOT YOU PLAN TO ATTEND, YOU ARE URGED TO COMPLETE, DATE,
SIGN AND RETURN THE ENCLOSED PROXY IN THE ACCOMPANYING ENVELOPE. A PROMPT
RESPONSE WILL GREATLY FACILITATE ARRANGEMENTS FOR THE MEETING AND YOUR
COOPERATION WILL BE APPRECIATED. STOCKHOLDERS WHO ATTEND THE MEETING MAY VOTE
THEIR STOCK PERSONALLY EVEN THOUGH THEY HAVE SENT IN THEIR PROXIES.
15
<PAGE> 18
ADVANCED MAGNETICS, INC.
PROXY FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD FEBRUARY 3, 1998
PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
P R O X Y
The undersigned, revoking all prior proxies, hereby appoint(s) Jerome
Goldstein and Edward B. Roberts, and each of them, with full power of
substitution, as proxies to represent and vote as designated herein, all shares
of stock of Advanced Magnetics, Inc. ("the Company") which the undersigned would
be entitled to vote if personally present at the Annual Meeting of Stockholders
of the Company to be held at the offices of the Company, 61 Mooney Street,
Cambridge, Massachusetts 02138, on Tuesday, February 3, 1998 at 10:00 a.m.,
local time, and at any adjournment thereof.
IN THEIR DISCRETION, THE PROXIES ARE AUTHORIZED TO VOTE UPON SUCH OTHER
MATTERS AS PROPERLY MAY COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF.
This proxy, when properly executed, will be voted in the manner
directed herein by the undersigned stockholder(s). IF NO DIRECTION IS GIVEN,
THIS PROXY WILL BE VOTED FOR THE ELECTION OF DIRECTORS AND AUTHORITY WILL BE
DEEMED GRANTED UNDER ITEM 2. Attendance of the undersigned at the meeting or at
any adjournment thereof will not be deemed to revoke this proxy unless the
undersigned shall revoke this proxy in writing.
CONTINUED AND TO BE SIGNED ON REVERSE SIDE
SEE REVERSE SIDE
/X/ PLEASE MARK
VOTES AS IN
THIS EXAMPLE.
1. To Elect Directors.
NOMINEES: Leonard M. Baum, Jerome Goldstein, Leslie Goldstein, Joseph Lassiter,
III, Michael Loberg, Edward B. Roberts, and George M. Whitesides
FOR WITHHELD
/ / / /
/ /
________________________________
For all nominees except as noted above
2. To transact such other business as may properly come before the Meeting.
MARK HERE MARK HERE IF
FOR ADDRESS / / YOU PLAN TO / /
CHANGE AND ATTEND THE
NOTE AT LEFT MEETING
Sign as name appears. Joint owners must both sign. Attorney, executor,
administrator, trustee or guardian must give title. A corporation or partnership
must sign in its name by authorized person.
Signature:_________________________Date:_____________
Signature:_________________________Date:_____________
14
